To assess response of tumor to chemotherapy given before surgery by using PET CT scan.
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Patients taking treatment of cancer
- Registration Number
- CTRI/2014/07/004767
- Lead Sponsor
- ot Applicable
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 75
Inclusion Criteria
All operated patients of esophageal adenocarcinoma who have undergone pre and post neo-adjuvant chemotherapy FDG PET/CT.
Exclusion Criteria
Previously operated patients
Patients who have not undergone either the baseline or the post NACT PET/CT
Patients who have received chemotherapy or radiation therapy prior to the initial PET/CT.
Patients who are operated without receiving NACT.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary objective <br/ ><br>1) To evaluate the ability of FDG PET/CT in predicting histopathological response after neo-adjuvant chemotherapy in patients with adenocarcinoma of the gastroesophageal junction. <br/ ><br>Timepoint: 2 years
- Secondary Outcome Measures
Name Time Method 1.To assess if reduction in metabolism on FDG PET predict disease free survival (DFS) <br/ ><br>2. To compare morphological response with histopathological response. <br/ ><br>Timepoint: 2 years